Insulinemia and the risk of breast cancer and its relapse

Diabetes, Obesity and Metabolism

Volumn 14, Issue 12, 2012, Pages 1073-1080

  Formica, Vincenzo ^a   Tesauro, M ^b   Cardillo, C ^c   Roselli, M ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Breast cancer; C peptide; HOMA IR; Insulin resistance

Indexed keywords

C PEPTIDE; ESTRADIOL; INSULIN; INSULIN RECEPTOR; OCTREOTIDE; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC AGENT;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MODEL; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; DISEASE ASSOCIATION; HORMONE ACTION; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULINEMIA; MASTECTOMY; META ANALYSIS (TOPIC); NONHUMAN; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TUMOR PROMOTION; BLOOD; BREAST NEOPLASMS; COMPLICATION; DISEASE COURSE; FEMALE; HYPERINSULINISM; NEOPLASM RECURRENCE, LOCAL; OBESITY; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; CANCER GROWTH; CANCER MORTALITY; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; OVERALL SURVIVAL; RECURRENCE RISK;

BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERINSULINISM; INSULIN RESISTANCE; NEOPLASM RECURRENCE, LOCAL; OBESITY; PROGNOSIS; RISK FACTORS;

EID: 84873254209     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2012.01614.x     Document Type: Review

References (40)

1. Muniyappa R, Lee S, Chen H, Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008; 294: E15-26.
2. Campia U, Tesauro M, Cardillo C. Human obesity and endotheliumdependent responsiveness. Br J Pharmacol 2011; 165: 561-573.
3. Tesauro M, Cardillo C. Obesity, blood vessels and metabolic syndrome. Acta Physiol (Oxf) 2011; 203: 279-286.
4. Cardillo C, Kilcoyne CM, Nambi SS, Cannon RO 3rd., Quon MJ, Panza JA. Vasodilator response to systemic but not to local hyperinsulinemia in the human forearm. Hypertension 1998; 32: 740-745.
5. Schinzari F, Tesauro M, Rovella V et al. Generalized impairment of vasodilator reactivity during hyperinsulinemia in patients with obesityrelated metabolic syndrome. Am J Physiol Endocrinol Metab 2010; 299: E947-952.
6. Tesauro M, Schinzari F, Rovella V et al. Tumor necrosis factor-alpha antagonism improves vasodilation during hyperinsulinemia in metabolic syndrome. Diabetes Care 2008; 31: 1439-1441.
7. Rask-Madsen C, Li Q, Freund B et al. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab 2010; 11: 379-389.
8. Peairs KS, Barone BB, Snyder CF et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 2011; 29: 40-46.
9. Ewertz M, Jensen MB, Gunnarsdóttir Ká et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 2011; 29: 25-31.
10. Barroso I, Gurnell M, Crowley VE et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880-883.
11. Paonessa F, Foti D, Costa V et al. Activator protein-2 overexpression accounts for increased insulin receptor expression in human breast cancer. Cancer Res 2006; 66: 5085-5093.
12. Milazzo G, Giorgino F, Damante G et al. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res 1992; 52: 3924-3930.
13. DeCensi A, Gennari A. Insulin breast cancer connection: confirmatory data set the stage for better care. J Clin Oncol 2011; 29: 7-10.
14. Cezard JP, Forgue-Lafitte ME, Chamblier MC, Rosselin GE. Growthpromoting effect, biological activity, and binding of insulin in human intestinal cancer cells in culture. Cancer Res 1981; 41: 1148-1153.
15. Ng ST, Zhou J, Adesanya OO, Wang J, LeRoith D, Bondy CA. Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nat Med 1997; 3: 1141-1144.
16. Hankinson SE, Willett WC, Colditz GA et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 1393-1396.
17. Turkington RW, Hilf R. Hormonal dependence of DNA synthesis in mammary carcinoma cells in vitro. Science 1968; 160: 1457-1459.
18. Di Renzo J, Signoretti S, Nakamura N et al. Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res 2002; 62: 89-98.
19. Novosyadlyy R, Lann DE, Vijayakumar A et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 2010; 70: 741-751.
20. Ferguson RD, Novosyadlyy R, Fierz Y et al. Hyperinsulinemia enhances c- Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. Breast Cancer Res 2012; 14: R8.
21. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 2008; 114: 63-70.
22. Gunter MJ, Hoover DR, Yu H et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009; 101: 48-60.
23. Kabat GC, Kim M, Caan BJ et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int J Cancer 2009; 125: 2704-2710.
24. Mink PJ, Shahar E, Rosamond WD, Alberg AJ, Folsom AR. Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol 2002; 156: 349-352.
25. Lawlor DA, Smith GD, Ebrahim S. Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. Cancer Causes Control 2004; 15: 267-275.
26. Kaaks R, Lundin E, Rinaldi S et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 2002; 13: 307-316.
27. Keinan-Boker L, Bueno De Mesquita HB, Kaaks R et al. Circulating levels of insulin-like growth factor I, its binding proteins -1,-2, -3, C-peptide and risk of postmenopausal breast cancer. Int J Cancer 2003; 106: 90-95.
28. Al-Delaimy WK, Flatt SW, Natarajan L et al. IGF1 and risk of additional breast cancer in the WHEL study. Endocr Relat Cancer 2011; 18: 235-244.
29. Duggan C, Irwin ML, Xiao L et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 2011; 29: 32-39.
30. Irwin ML, Duggan C, Wang CY et al. Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol 2011; 29: 47-53.
31. Pritchard KI, Shepherd LE, Chapman JA et al. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol 2011; 29: 3869-3876.
32. Oh SW, Park CY, Lee ES et al. Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res 2011; 13: R34.
33. Berrino F, Pasanisi P, Bellati C et al. Serum testosterone levels and breast cancer recurrence. Int J Cancer 2005; 113: 499-502.
34. Borugian MJ, Sheps SB, Kim-Sing C et al. Insulin, macronutrient intake, and physical activity: are potential indicators of insulin resistance associated with mortality from breast cancer? Cancer Epidemiol Biomarkers Prev 2004; 13: 1163-1172.
35. Goodwin PJ, Ennis M, Pritchard KI et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002; 20: 42-51.
36. Ligibel JA, Campbell N, Partridge A et al. Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol 2008; 26: 907-912.
37. Chlebowski RT, Pettinger M, Stefanick ML, Howard BV, Mossavar- Rahmani Y, McTiernan A. Insulin, physical activity, and caloric intake in postmenopausal women: breast cancer implications. J Clin Oncol 2004; 22: 4507-4513.
38. Jiralerspong S, Palla SL, Giordano SH et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27: 3297-3302.
39. Formica V, Grenga I, Tesauro M et al. Metabolic syndrome (MetS) in metastatic (m) colorectal cancer (CRC) patients (pts) might delay the onset of cachexia. Eur J Cancer 2011; 47S: S241.
40. Formica V, Rodia G, Grenga I et al. Brachial artery(ba) flow-mediated dilation(FMD) test may detect endothelial dysfunction in patients treated with standard fluorouracil/irinotecan/bevacizumab(FOLFIRI-B) chemotherapy. Tumori 2011; 11: S102.